Share：
Share this content in WeChat
X
[Chinese][PDF]72730
• Clinical Article •
The value of predicting the PR expression status of meningiomas based on MRI features
LI Zhengxiao  XUE Caiqiang  LI Shenglin  SUN Jiachen  LIU Suwei  REN Tiezhu  ZHOU Junlin 

Cite this article as: Li ZX, Xue CQ, Li SL, et al. The value of predicting the PR expression status of meningiomas based on MRI features[J]. Chin J Magn Reson Imaging, 2022, 13(7): 1-5. DOI:10.12015/issn.1674-8034.2022.07.001.


[Abstract] Objective To explore whether preoperative MRI features can distinguish the expression status of progesterone receptor (PR) in meningiomas, and provide preoperative prediction basis for meningioma with positive PR expression.Materials and Methods The preoperative MRI data of 210 patients with meningioma who were confirmed by surgery and pathology and whose PR expression status was determined from June 2020 to December 2021 in our hospital were retrospectively analyzed. According to PR expression, they were divided into PR positive (+) group and PR negative (-) group. Univariate analysis was performed on the preoperative MRI images of the two groups of patients, and the independent predictors of PR positive expression in meningiomas were screened by logistic multivariate regression analysis. According to the parameters with statistically significant differences, the receiver operating characteristic (ROC) curve of the participants was drawn, and the area under the curve (AUC) was calculated to evaluate the effectiveness in predicting PR expression status.Results Among the 210 meningiomas, 79 were PR (+) and 131 were PR (-). Univariate analysis showed that between the two groups had statistical differences in the location of meningioma, cystic change and enhancement pattern (P＜0.05). There was no statistical difference in gender, age, maximum tumor diameter, tumor-brain interface, peritumoral edema, dural tail sign, and ADC value (P＞0.05); logistic multivariate regression analysis showed that tumor location, enhancement method were independent predictors of PR positive expression in meningiomas. ROC curve analysis showed that the AUC values of tumor location and enhancement method for predicting PR positive expression were 61.9% and 62.4%, respectively.Conclusions MRI features can predict the PR expression status of meningiomas before surgery; meningiomas located in the skull base and uniform enhancement of the tumor can indirectly express PR positive.
[Keywords] meningioma；progesterone receptor；progesterone receptor expression；magnetic resonance imaging；imaging features

LI Zhengxiao1, 2, 3, 4   XUE Caiqiang1, 2, 3, 4   LI Shenglin1, 2, 3, 4   SUN Jiachen1, 2, 3, 4   LIU Suwei1, 2, 3, 4   REN Tiezhu1, 2, 3, 4   ZHOU Junlin1, 2, 3, 4*  

1 Department of Radiology, Lanzhou University Second Hospital, Lanzhou 730030, China

2 Second Clinical School, Lanzhou University, Lanzhou 730030, China

3 Key Laboratory of Medical Imaging of Gansu Province, Lanzhou 730030, China

4 Gansu International Scientific and Technological Cooperation Base of Medical Imaging Artificial Intelligence, Lanzhou 730030, China

Zhou JL, E-mail: LZUzjl601@163.com

Conflicts of interest   None.

ACKNOWLEDGMENTS National Natural Science Foundation of China (No. 82071872); Science and Technology Program Funding Project of Gansu Province (No. 21YF5FA123).
Received  2022-03-09
Accepted  2022-07-05
DOI: 10.12015/issn.1674-8034.2022.07.001
Cite this article as: Li ZX, Xue CQ, Li SL, et al. The value of predicting the PR expression status of meningiomas based on MRI features[J]. Chin J Magn Reson Imaging, 2022, 13(7): 1-5. DOI:10.12015/issn.1674-8034.2022.07.001.

[1]
Maggio I, Franceschi E, Tosoni A, et al. Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas[J/OL]. CNS10(2) [2022-03-09]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162186/pdf/cns-10-72.pdf. DOI: 10.2217/cns-2021-0003.
[2]
Goldbrunner R, Stavrinou P, Jenkinson MD, et al. EANO guideline on the diagnosis and management of meningiomas[J]. Neuro Oncol, 2021, 23(11): 1821-1834. DOI: 10.1093/neuonc/noab150.
[3]
Benson VS, Pirie K, Green J, et al. Hormone replacement therapy and incidence of central nervous system tumours in the Million Women Study[J]. Int J Cancer, 2010, 127(7): 1692-1698. DOI: 10.1002/ijc.25184.
[4]
Andersen L, Friis S, Hallas J, et al. Hormone replacement therapy increases the risk of cranial meningioma[J]. Eur J Cancer, 2013, 49(15): 3303-3310. DOI: 10.1002/ijc.25184.
[5]
Graillon T, Boissonneau S, Appay R, et al. Meningiomas in patients with long-term exposition to progestins: Characteristics and outcome[J]. Neurochirurgie, 2021, 67(6): 556-563. DOI: 10.1016/j.neuchi.2021.04.018.
[6]
Achey RL, Gittleman H, Schroer J, et al. Nonmalignant and malignant meningioma incidence and survival in the elderly, 2005-2015, using the Central Brain Tumor Registry of the United States[J]. Neuro Oncol, 2019, 21(3): 380-391. DOI: 10.1093/neuonc/noy162.
[7]
Giraldi L, Lauridsen EK, Maier AD, et al. Pathologic Characteristics of Pregnancy-Related Meningiomas[J]. Cancers (Basel), 2021, 13(15): 3879. DOI: 10.3390/cancers13153879.
[8]
Goldbrunner R, Minniti G, Preusser M, et al. EANO guidelines for the diagnosis and treatment of meningiomas[J/OL]. Lancet Oncol, 2016, 17(9) [2022-03-09]. https://linkinghub.elsevier.com/retrieve/pii/S1470204516303217. DOI: 10.1016/S1470-2045(16)30321-7.
[9]
Raban D, Patel SH, Honce JM, et al. Intracranial meningioma surveillance using volumetrics from T2-weighted MRI[J]. J Neuroimaging, 2022, 32(1): 134-140. DOI: 10.1111/jon.12926.
[10]
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary[J]. Neuro Oncol, 2021, 23(8): 1231-1251. DOI: 10.1093/neuonc/noab106.
[11]
Azeez J M, Susmi TR, Remadevi V, et al. New insights into the functions of progesterone receptor (PR) isoforms and progesterone signaling[J]. Am J Cancer Res, 2021, 11(11): 5214-5232.
[12]
Carroll RS, Glowacka D, Dashner K, et al. Progesterone receptor expression in meningiomas[J]. Cancer Res, 1993, 53(6): 1312-1316.
[13]
Ikeri NZ, Anunobi CC, Bankole OB. Progesterone receptor expression and Ki-67 labelling index of meningiomas in the Lagos university teaching hospital[J]. Niger Postgrad Med J, 2018, 25(1): 17-20. DOI: 10.4103/npmj.npmj_16_18.
[14]
Hage M, Plesa O, Lemaire I, et al. Estrogen and Progesterone Therapy and Meningiomas[J/OL]. Endocrinology, 2022, 163(2) [2022-03-09]. https://academic.oup.com/endo/article-abstract/163/2/bqab259/6479628?redirectedFrom=fulltext. DOI: 10.1210/endocr/bqab259.
[15]
Gao P, Xiang QM, Yang Y, et al. Clinicopathological characteristics and the differences analysis of expression of PR, ER and AR in different grades of meningiomas[J]. China Medicine Herald, 2021, 18(22): 17-21, 198.
[16]
Kuroi Y, Matsumoto K, Shibuya M, et al. Progesterone Receptor Is Responsible for Benign Biology of Skull Base Meningioma[J/OL]. World Neurosurg, 2018, 118 [2022-03-09]. https://linkinghub.elsevier.com/retrieve/pii/S187887501831578X. DOI: 10.1016/j.wneu.2018.07.100.
[17]
Maiuri F, Mariniello G, De Divitlls O, et al. Progesterone Receptor Expression in Meningiomas: Pathological and Prognostic Implications[J/OL]. Front Oncol, 2021, 11 [2022-03-09]. https://www.frontiersin.org/articles/10.3389/fonc.2021.611218/full. DOI: 10.3389/fonc.2021.611218.
[18]
Mnango L, Mwakimonga A, Ngaiza AI, et al. Expression of Progesterone Receptor and Its Association with Clinicopathological Characteristics in Meningiomas: A Cross-Sectional Study[J/OL]. World Neurosurg X, 2021, 12 [2022-03-09]. . https://linkinghub.elsevier.com/retrieve/pii/S2590139721000144. DOI: 10.1016/j.wnsx.2021.100111.
[19]
Passeri T, Giammattei L, Le Van T, et al. Atypical evolution of meningiomatosis after discontinuation of cyproterone acetate: clinical cases and histomolecular characterization[J]. Acta Neurochir (Wien), 2022, 164(1): 255-263. DOI: 10.1007/s00701-021-05005-9.
[20]
Boetto J, Peyre M, Kalamarides M. Meningiomas from a developmental perspective: exploring the crossroads between meningeal embryology and tumorigenesis[J]. Acta Neurochir (Wien), 2021, 163(1): 57-66. DOI: 10.1007/s00701-020-04650-w.
[21]
Okano A, Miyawaki S, Hongo H, et al. Associations of pathological diagnosis and genetic abnormalities in meningiomas with the embryological origins of the meninges[J]. Sci Rep, 2021, 11(1): 6987. DOI: 10.1038/s41598-021-86298-9.
[22]
Maiuri F, Mariniello G, Guadagno E, et al. WHO grade, proliferation index, and progesterone receptor expression are different according to the location of meningioma[J]. Acta Neurochir (Wien), 2019, 161(12): 2553-2561. DOI: 10.1007/s00701-019-04084-z.
[23]
Nakasu S, Fukami T, Jito J, et al. Recurrence and regrowth of benign meningiomas[J]. Brain Tumor Pathol, 2009, 26(2): 69-72. DOI: 10.1007/s10014-009-0251-2.
[24]
Turner N, Kaye AH, Paldor I. Metastases to meningioma-review and meta-analysis[J]. Acta Neurochir (Wien), 2021, 163(3): 699-709. DOI: 10.1007/s00701-020-04661-7.
[25]
Bozdag M, Er A, Ekmekci S. Association of apparent diffusion coefficient with Ki-67 proliferation index, progesterone-receptor status and various histopathological parameters, and its utility in predicting the high grade in meningiomas[J]. Acta Radiol, 2021, 62(3): 401-413. DOI: 10.1177/0284185120922142.
[26]
Wrobel G, Roerig P, Kokocinski F, et al. Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression[J]. Int J Cancer, 2005, 114(2): 249-256. DOI: 10.1002/ijc.20733.
[27]
Mukherjee S, Ghosh SN, Chatterjee U, et al. Detection of progesterone receptor and the correlation with Ki-67 labeling index in meningiomas[J]. Neurol India, 2011, 59(6): 817-822. DOI: 10.4103/0028-3886.91357.

PREV Application progress of imaging technology in high-pressure injection injury
NEXT The value of predicting the subtype of IDH mutation combining with MGMT promoter methylation in lower grade gliomas by radiomics based on preoperative MRI
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn